Research programme: premature ejaculation therapeutic - NeuroHealing

Drug Profile

Research programme: premature ejaculation therapeutic - NeuroHealing

Alternative Names: NH 02D

Latest Information Update: 10 May 2013

Price : $50

At a glance

  • Originator NeuroHealing Pharmaceuticals
  • Class Benzhydryl compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Premature ejaculation

Most Recent Events

  • 10 May 2013 NeuroHealing Pharmaceuticals plans a phase II trial for Premature ejaculation in USA
  • 10 May 2013 Preclinical development is ongoing in USA
  • 13 Apr 2009 Pharmacodynamics data from a preclinical trial in Premature ejaculation released by NeuroHealing Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top